Eisai Establishes Pharma Sales Subsidiary in Vietnam

Sep 17, 2020 09:59 JST

Source: Eisai

TOKYO, Sep 17, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam (Vietnam), which will be named Eisai Vietnam Co., Ltd. (Eisai Vietnam). Eisai Vietnam is a wholly-owned subsidiary of Eisai.

The pharmaceutical market in Vietnam is surpassed in size only by those of Thailand and the Philippines within the Association of Southeast Asian Nations (ASEAN), with the market size reaching 4,199 million USD in 20191. The compound annual growth rate of the Vietnamese pharmaceutical market from 2014 to 2019 was +10.6%(1), and it is expected that this market rate will continue to grow in the double digits. In 1992, Eisai (Thailand) Marketing Co., Ltd., a pharmaceutical sales subsidiary of Eisai, started business in Vietnam through a local agency. Eisai opened a representative office in Ho Chi Minh City in 1995, and mainly markets the proton-pump inhibitor Pariet, muscle relaxant Myonal, peripheral neuropathy treatment Methycobal, and others.

In addition, regarding its global products in Vietnam, Eisai recently launched its antiepileptic drug Fycompa in October 2019, and obtained marketing approval for the anti-cancer agent Lenvima in June 2020. Eisai has also filed for regulatory approval for the in-house developed anti-cancer agent Halaven.

With the establishment of Eisai Vietnam, Eisai aims to enhance its own drug sales system in Vietnam, deliver innovative new drugs to more patients in Vietnam, and contribute to improving the benefits of patients and their families.

(1) Copyright 2020 IQVIA Created based on IQVIA Analytics Link 2014-2019. Unauthorized reproduction prohibited.

Contact:

Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month

September 12 2025 12:20 JST

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025

September 08 2025 16:49 JST

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

September 04 2025 09:56 JST

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

September 03 2025 10:32 JST

FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

September 01 2025 12:44 JST

Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma

August 29 2025 17:17 JST

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)

August 25 2025 18:30 JST

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China

August 18 2025 08:11 JST

Revenue of LEQEMBI(R) (Preliminary Basis)

July 31 2025 17:27 JST

Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

July 31 2025 08:30 JST

More Press release >>

Latest Press Release

JSR Corporation/Inpria Corporation and Lam Research Enter Cross Licensing and Collaboration Agreement to Advance Semiconductor Manufacturing
Sep 16, 2025 09:00 JST

Toyota Launches Next-Generation New Mobility e-Palette
Sep 15, 2025 15:33 JST

The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sep 12, 2025 15:08 JST

GR Yaris "Aero performance package" Set for Japan Launch
Sep 12, 2025 14:40 JST

Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems

Sep 12, 2025 14:19 JST

"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sep 12, 2025 13:20 JST

TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sep 12, 2025 11:00 JST

CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates to Be Utilized in Nagaoka Methanation Demonstration
Sep 11, 2025 20:37 JST

Hitachi accelerates growth with major U.S. investments in advanced manufacturing, electrification and workforce development

Sep 11, 2025 18:35 JST

GlobalLogic and Ericsson Deploy Private 5G Network at Hitachi Rail's State-of the-Art Digital Factory
Sep 11, 2025 17:24 JST

GlobalLogic and Flexware Innovation Announce Major Deployment of LIFT at Hitachi Rail's State-of-the-Art Train Manufacturing Facility
Sep 11, 2025 16:46 JST

JCB Unveils New Brand Message in Vietnam: "Japan Cung Ban"
Sep 11, 2025 13:00 JST

Kawasaki City becomes first dekokatsu subsidy municipality for promoting decarbonization lifestyle promotion project
Sep 11, 2025 10:35 JST

TGR Plans to Reproduce Engine Parts for Corolla Levin / Sprinter Trueno (AE86)
Sep 10, 2025 18:11 JST

TANAKA Acts as Category Sponsor for the LIGA.i Blind Soccer Top League 2025
Sep 10, 2025 03:00 JST

Toyota Submits Fourth Progress Report on Measures to Prevent Recurrence
Sep 09, 2025 19:26 JST

The 46th Honda Prize 2025 Awarded to Dr. Kenichi IGA
Sep 09, 2025 19:06 JST

Lexus world premieres the new IS
Sep 09, 2025 18:26 JST

Toni Bou Wins 19th Consecutive FIM Trial World Championship Title
Sep 08, 2025 18:53 JST

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sep 08, 2025 17:49 JST

More Latest Release >>